Literature DB >> 25712382

Autophagy in Natural History and After ERT in Glycogenosis Type II.

Corrado Angelini1, Anna C Nascimbeni, Marina Fanin.   

Abstract

We studied the role of autophagy in a series of 10 infantile-, juvenile-, and adult-onset GSDII patients and investigated autophagy blockade in successive biopsies of adult cases during disease natural history. We also correlated the autophagosome accumulation and efficiency of enzyme replacement therapy (ERT) in four treated cases (two infantile and two juvenile-adult onsets).The autophagic flux was monitored by measuring the amount of p62-positive protein aggregates and compared, together with fibre vacuolisation, to fibre atrophy.A blocked autophagic flux resulted in p62 accumulation, increased vacuolisation, and progressive atrophy of muscle fibres in biopsies collected from patients during natural history. On the contrary, in the GSDII cases early treated with ERT, the autophagic flux improved and muscle fibre atrophy, fibre vacuolisation, and acid phosphatase activity decreased.The functionality of the autophagy-lysosome system is essential in GSDII muscle, which is characterised by the presence of swollen glycogen-filled lysosomes and autophagic build-up. Defining the role of autophagy and its relationship with muscle loss is critical for understanding the disease pathogenesis, for developing new therapies, and for improving ERT efficacy in GSDII.

Entities:  

Year:  2015        PMID: 25712382      PMCID: PMC4470943          DOI: 10.1007/8904_2014_389

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  15 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Where do we stand in enzyme replacement therapy in Pompe's disease?

Authors:  A T van der Ploeg
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

3.  The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII).

Authors:  A C Nascimbeni; M Fanin; E Masiero; C Angelini; M Sandri
Journal:  Cell Death Differ       Date:  2012-05-18       Impact factor: 15.828

4.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

Authors:  S Strothotte; N Strigl-Pill; B Grunert; C Kornblum; K Eger; C Wessig; M Deschauer; F Breunig; F X Glocker; S Vielhaber; A Brejova; M Hilz; K Reiners; W Müller-Felber; E Mengel; M Spranger; Benedikt Schoser
Journal:  J Neurol       Date:  2009-08-01       Impact factor: 4.849

5.  Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.

Authors:  Laura Deroma; Mattia Guerra; Annalisa Sechi; Giovanni Ciana; Giorgia Cisilino; Andrea Dardis; Bruno Bembi
Journal:  Eur J Pediatr       Date:  2014-01-07       Impact factor: 3.183

6.  Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation.

Authors:  P Laforêt; M Nicolino; P B Eymard; J P Puech; C Caillaud; L Poenaru; M Fardeau
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

7.  Late-onset Pompe disease primarily affects quality of life in physical health domains.

Authors:  M L C Hagemans; A C J W Janssens; L P F Winkel; K A Sieradzan; A J J Reuser; P A Van Doorn; A T Van der Ploeg
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

8.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

9.  Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...

Authors:  Nina Raben; Shoichi Takikita; Maria G Pittis; Bruno Bembi; Suely K N Marie; Ashley Roberts; Laura Page; Priya S Kishnani; Benedikt G H Schoser; Yin-Hsiu Chien; Evelyn Ralston; Kanneboyina Nagaraju; Paul H Plotz
Journal:  Autophagy       Date:  2007-06-15       Impact factor: 16.016

Review 10.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.